![Gary Lee](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 158 794 $ al 30/09/2026
Gary Lee is currently Chief Scientific Officer at Lyell Immunopharma, Inc. since 2022.
Formerly, Dr. Lee was Vice President-Cell Therapy at Sangamo Therapeutics, Inc. from 2005 to 2018 and Chief Scientific Officer at Senti Sub I, Inc. from 2018 to 2022.
Education includes undergraduate studies at California Institute of Technology and a doctorate from the University of California, Berkeley.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
LYELL IMMUNOPHARMA, INC. 0,07 % | 21/08/2026 | 16.220 ( 0,07 % ) | 158 794 $ | 30/09/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| LYELL IMMUNOPHARMA, INC. | Director Técnico/Científico/I+D | 31/01/2022 |
| Empresas | Cargo | Fin |
|---|---|---|
Senti Sub I, Inc.
 Senti Sub I, Inc. BiotechnologyHealth Technology Develops novel therapeutics | Director Técnico/Científico/I+D | 01/01/2022 |
| SANGAMO THERAPEUTICS, INC. | Corporate Officer/Principal | 01/10/2018 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
Sangamo Therapeutics, Inc.
 Sangamo Therapeutics, Inc. BiotechnologyHealth Technology Operates as a genomic medicine company | Health Technology |
California Institute of Technology
 California Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Senti Sub I, Inc.
Senti Sub I, Inc. BiotechnologyHealth Technology Develops novel therapeutics | Health Technology |
Lyell Immunopharma, Inc.
 Lyell Immunopharma, Inc. BiotechnologyHealth Technology Develops cell-based immunotherapies for human diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
